Netting its biggest fish to date, Patriot Scientific Corporation has sold Hewlett-Packard a license to use intellectual property protected by the Moore Microprocessor Patent Portfolio, which the Southern California company owns jointly with the TPL Group.
The drawn out lawsuit by software maker MicroStrategy Inc. against French rival Business Objects SA has been deflated by a federal judge, who found the asserted patents to be either invalid or not infringed.
DataTreasury, the tiny check processing company that has aggressively asserted its patents against banking giants like Citigroup and Bank of America, has won yet another settlement, this time in its case against global technology company NCR Corporation.
In their duel over domination of the electronic trading business, Reuters and Bloomberg LP are temporarily sheathing their swords as they prepare to settle a lawsuit Reuters brought against Bloomberg for allegedly infringing patents for its automated trading technology.
In the battle over a prostate cancer treatment, an Illinois federal court handed Takeda Abbott Pharmaceuticals Inc. another key victory this week after rejecting the patent “unenforceability” defense asserted by pharmaceutical companies QLT USA Inc. and Sanofi-Synthelabo Inc.
The U.S. Court of Appeals for the Federal Circuit overstepped its bounds by reviewing the sufficiency of evidence in a patent infringement and antitrust case, according to a decision on Monday by the U.S. Supreme Court.
Mired in patent lawsuits, medical device maker Medtronic Inc. has decided to pay $37.5 million to settle litigation with its latest accuser, a California biotechnology company that specializes in heart valves.
The U.S. Supreme Court has pushed BlackBerry maker Research In Motion Ltd. closer than ever to a service-stopping injunction or a financially painful settlement with patent-holding company NTP Inc., after declining to hear RIM’s appeal.
Shire Pharmaceuticals Group PLC has penned a settlement deal with generic challenger Impax over a blockbuster drug for hyperactivity.
San Francisco law firm Morrison & Foerster LLP has dealt a lethal blow to the Silicon Valley satellite of Milbank Tweed Hadley & McCloy by luring its top intellectual property partner with benefits unique to a general practice powerhouse.
Internet search company Google Inc. has said its intellectual property would be compromised if it complied with a White House demand to turn over huge amounts of search activity conducted by users.
Another high-ranking trial attorney has joined the swelling ranks of Quinn Emanuel Urquhart Oliver & Hedges, LLP, marking the firm’s second big catch in a week.
A former Columbia University medical student who claimed he helped develop a treatment for glaucoma will not be listed as a co-inventor on the patent, a federal appeals court has ruled.
A Japanese pharmaceutical company has slapped Israeli generic drug maker Teva Pharmaceuticals Industries Ltd. with a patent infringement lawsuit in a battle over a drug used to treat acid reflux.
A group of college students that was sued by the entertainment industry for alleged copyright infringement is trying to force the creator of a file-sharing network to fund a possible settlement with the organization.
Patent holding company NTP Inc. is siding with its adversary, Research In Motion Ltd., on the contentious issue of government-held BlackBerry devices, hoping to win an injunction by agreeing the workers be exempt from a possible service blackout.
The U.S. Court of Appeals for the Federal Circuit has given the green light to Microsoft in its bid to request that a new judge preside over a federal patent trial in which the software giant hopes to avoid paying at least $561 million in damages.
After last year’s record-breaking $1.4 billion payout to a Los Angeles surgeon, medical device maker Medtronic Inc. is now facing charges that it illegally sought patents based on the inventions of a New York orthopedic spine surgeon.
Pharmaceutical giant AstraZeneca has lost a key U.S. court ruling concerning two patents covering the heart drug Toprol-XL in the latest setback in the company’s struggle to sustain its pipeline of blockbuster medications.
Pfizer, deflecting challenges from several generic drug makers over the patents for its second best-selling drug Norvasc, has prevailed in one of the cases, with a judge blocking an attempt by Apotex to launch a generic version of the blood pressure treatment.